BlackRock’s Rani Therapeutics RANI Stock Holding History
Bought
Maintained
Sold
Other funds holding RANI
SB
RCM
AIC
LP
PAMP
SL
HCM
BlackRock's RANI Position: Q2 2026 in Review
BlackRock reduced its Rani Therapeutics (RANI) stake by 39% in Q2 2026, selling an estimated $190K and leaving 342,113 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #4746.
BlackRock first reported a position in RANI in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.14M in Q2 2022. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.
- BlackRock held 342,113 shares of Rani Therapeutics worth $260K as of Q2 2026.
- BlackRock sold 214,776 Rani Therapeutics shares in Q2 2026, an estimated $190K.
- Rani Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4746 holding.
- BlackRock first reported a position in Rani Therapeutics in Q4 2021 and has held it in 19 quarters since.
- BlackRock's Rani Therapeutics position peaked at $2.14M in Q2 2022.
- 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.